Horizon Discovery Announces Strategic Partnership with Promega to Develop Next-Generation Predictive Human Disease Models
Horizon Discovery Ltd. announced a strategic partnership agreement with Promega Corporation. The partnership centers on the delivery of endogenous gene reporting capabilities, in the form of Promega’s luciferase and HaloTag® reporter technologies, using Horizon’s proprietary homologous recombination-based precision genome editing technology (rAAV GENESIS™).
The scientific objective of the partnership is to develop next-generation predictive human disease models, recapitulating genetic mutations exactly as they occur in patient tumors, thereby enabling the elucidation of protein expression and protein-protein interactions encoded by those mutations. To date, Horizon has applied its rAAV gene-editing platform to reconstitute over 370 cancer mutations and variations in human cell lines that serve as patient-relevant, predictive in vitro models of genetic disease.
Additional objective(s) will be to enable the study of tumor response to anti-cancer treatments in real-time, by offering in vivo xenografts of Horizon’s tumorigenic engineered isogenic cell lines with incorporated Promega reporter tags. Preliminary studies have revealed exceptionally clear images of tumor graft response to targeted molecular therapies. This capability adds to drug discovery scientists’ existing toolbox of patient relevant models to support the development of a greater number of more efficacious anti-cancer drugs.
Topics
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Triple-threat cancer-fighting polymer capsules for guided drug delivery created
New prostate cancer treatment may be riskier
Genzyme and Bayer HealthCare Enter New Strategic Agreement - Genzyme Assumes Primary Responsibility for the Development and Commercialization of Alemtuzumab for Multiple Sclerosis

Billion-euro takeover: Roche joins the fight against obesity
Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
Immune system reveals new ways to treat brain disease and pain
Genomatix partners with Research Instruments Pte Ltd for Singapore, Malaysia and Thailand markets

The 2013 Nobel Prize in Physiology or Medicine: Machinery regulating vesicle traffic

Pharmaceutical research knocking on wood - Researchers establish green pharmaceutical production from wood waste
Twin nanoparticle shown effective at targeting, killing breast cancer cells
CureVac enters clinical phase with mRNA vaccine - First data expected on intramuscular application of the newly developed vaccine
